quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 2, 2026

Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances

View original at finance.yahoo.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances GALWAY, Ireland, Feb…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • MiniMed 780G system automatically adjusts insulin delivery every five minutes, responding to glucose changes, supporting more stable glucose control with fewer highs and lows and less daily decision-making

    80% confidence
  • More people living with type 2 diabetes will get access to life-changing technology improving their day-to-day experience in managing their diabetes

    80% confidence
  • Bringing together the Instinct sensor with the well-established algorithm of the MiniMed 780G system makes for an extremely effective combination

    80% confidence
  • Medtronic technologies and therapies treat 70 health conditions and transform the lives of two people every second, every hour, every day

    80% confidence
  • These milestones reflect unwavering commitment to expanding access and giving individuals living with diabetes more choice in how they manage their condition

    80% confidence
  • By broadening sensor and insulin options for the MiniMed 780G system, more people will benefit from automated insulin delivery that supports easier mealtimes, greater flexibility, and more confident diabetes management

    80% confidence
  • Instinct sensor offers up to 15 days of wear and is the world's smallest and thinnest integrated CGM

    80% confidence
  • Ultra rapid-acting insulin's faster onset may help reduce the impact of late or missed meal doses, allowing the insulin to catch up more effectively

    80% confidence
  • Anyone who requires insulin therapy to manage their diabetes, whether type 1 or type 2, can benefit from automated insulin delivery

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances — Source | Via News | pt.VIA.NEWS